Rice Hall James & Associates LLC Acquires New Holdings in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH)

Rice Hall James & Associates LLC purchased a new stake in Aurinia Pharmaceuticals Inc (NASDAQ:AUPH - Free Report) TSE: AUP during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 225,470 shares of the biotechnology company's stock, valued at approximately $1,813,000. Rice Hall James & Associates LLC owned approximately 0.17% of Aurinia Pharmaceuticals at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. acquired a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at $27,000. Tower Research Capital LLC TRC raised its holdings in Aurinia Pharmaceuticals by 368.5% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,350 shares of the biotechnology company's stock valued at $30,000 after acquiring an additional 2,635 shares in the last quarter. Vermillion & White Wealth Management Group LLC acquired a new stake in Aurinia Pharmaceuticals in the fourth quarter valued at $31,000. GAMMA Investing LLC raised its holdings in Aurinia Pharmaceuticals by 56.1% in the first quarter. GAMMA Investing LLC now owns 4,852 shares of the biotechnology company's stock valued at $39,000 after acquiring an additional 1,744 shares in the last quarter. Finally, Natixis acquired a new stake in shares of Aurinia Pharmaceuticals during the fourth quarter worth $49,000. 36.83% of the stock is owned by institutional investors and hedge funds.

Aurinia Pharmaceuticals Stock Performance

Shares of Aurinia Pharmaceuticals stock traded down $0.31 during trading on Friday, hitting $8.76. 913,976 shares of the stock were exchanged, compared to its average volume of 1,404,249. The stock's fifty day moving average is $8.12 and its 200 day moving average is $8.08. The stock has a market cap of $1.18 billion, a PE ratio of 31.20 and a beta of 1.16. The company has a debt-to-equity ratio of 0.16, a quick ratio of 5.26 and a current ratio of 5.93. Aurinia Pharmaceuticals Inc has a 12 month low of $5.20 and a 12 month high of $10.67.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its earnings results on Monday, May 12th. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.08 by $0.08. The firm had revenue of $62.47 million during the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a net margin of 16.11% and a return on equity of 14.27%. As a group, sell-side analysts anticipate that Aurinia Pharmaceuticals Inc will post 0.11 EPS for the current year.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Aurinia Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a research report on Thursday, March 27th.

Aurinia Pharmaceuticals Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.